JPRN-UMIN000025086招募中未知
Predictive and progonstic biomarkers of nivolumab and pembrolizumab treatment in Renal cell and urothelial carcinoma - BINIR study
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who are pregnant or have past history of allergy to immune checkpoint inhibitorsr will be excluded.
研究者
相似试验
已完成
不适用
Biomarker analysis: Phase II study of nivolumab + abemaciclib + endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer (NEWFLAME) WJOG11418B-TRHormone receptor positive and HER2-negative advanced breast cancerJPRN-UMIN000036970West Japan Oncology Group53
已完成
不适用
A Biomarker Analysis of Nivolumab in Previously Treated Advanced Gastric Cancer(WJOG10417GTR)Gastric CancerJPRN-UMIN000032686West Japan Oncology Group100
尚未招募
不适用
Biomarker Study for Combined nivolumab and ipilimumab in Fecal microbiota metabolites of Advanced malignant melanomaJPRN-UMIN000039666Japan Science and Technology Agency50
招募中
Unknown
A prospective observational study of nivolumab plus chemotherapy for advanced gastric cancer using CyberOncology (WJOG15922G)JPRN-UMIN000049928West Japan Oncology Group100
Unknown
不适用
Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell CarcinomaHNSCCDNA DamageDNA Double Strand BreakNCT03652142Attikon Hospital50